This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
GLP-1 Receptor Agonists: Injecting More Confidence in Achieving Glycemic Control for Patients With T2DM

GLP-1 Receptor Agonists: Injecting More Confidence in Achieving Glycemic Control for Patients With T2DM

Format

Webcast

Time to Complete

1 hour

Released

October 31, 2018

Expires

October 31, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Sanofi US

Program Description

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been embraced by management guidelines from the American Diabetes Association and the American Academy of Clinical Endocrinologists as an important treatment option for type 2 diabetes mellitus (T2DM). GLP-1 RAs improve both postprandial and fasting glucose levels without elevating hypoglycemia risk and can be used as monotherapy or as second-line treatment after metformin or other oral antidiabetes medications. GLP-1 RAs can achieve particular therapeutic synergies when used in combination with basal insulin, even countering the weight gain associated with insulin use. To that end, fixed-dose GLP-1 RA/basal insulin combinations are available, simplifying administration with a single daily injection. Yet many clinicians have been slow to use these medications in clinical practice for reasons that include clinical inertia, reluctance to initiate needle-delivered medications, and lack of familiarity with the class and the multiple individual agents within it.

To address these knowledge and practice gaps, this myCME TOWN WALLTM activity convenes diabetes experts to discuss evidence-based perspectives on GPL-1 RAs in T2DM: the pathophysiologic rationale; the underappreciation of the incidence and impact of hypoglycemia in T2DM; and characteristics of the various short- and long-acting GLP-1 RAs. The faculty will also provide their clinical perspectives how best to use GLP-1 RAs in practice—including patient-selection criteria, managing adverse effects of treatment, and coaching patients through initiation of injection therapy.

Intended Audience

Endocrinologists/diabetologists, family physicians, internal medicine physicians, nurse practitioners, and physician assistants.

Educational Objectives

After completing the activity, the participant should be better able to:

  • Evaluate the pharmacologic properties and safety profiles of the spectrum of short-acting and long-acting GLP-1 RAs
  • Analyze the limitations and benefits of individual GLP-1 RAs, including delivery technologies, that may advance glycemic control for patients with T2DM
  • Initiate dual GLP-1 RA/basal insulin therapy when appropriate in patients with T2DM
  • Implement strategies to address the lack of medication adherence and persistence among patients receiving GLP-1 RAs

Conflict Of Interest Disclosure Policies

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Faculty

Peter Salgo, MD, Moderator
Professor of Medicine and Anesthesiology
Columbia University College of Physicians and Surgeons
Associate Director, Surgical Intensive Care
Columbia University Medical Center
New York, NY

Dr. Salgo has no relevant financial relationships to disclose.

Daniel Einhorn, MD, FACP, FACE
Medical Director
Scripps Whittier Diabetes Institute
Clinical Professor of Medicine
University of California, San Diego
President, Diabetes and Endocrine Associates
La Jolla, CA

Dr. Einhorn receives consulting fees from AstraZeneca and Janssen Pharmaceuticals and is on the speakers’ bureaus for Janssen and Sanofi. Dr. Einhorn receives research funds from AstraZeneca, Janssen Pharmaceuticals, Lilly, MannKind Corporation, Novo Nordisk, and Sanofi. He has ownership interest in Epitracker, GlySens Incorporated, and Halozyme, Inc.

Javier Morales, MD, FACP, FACE
Clinical Associate Professor of Medicine
David and Barbara Zucker School of Medicine
  at Hofstra/Northwell at Hofstra University
Hempstead, NY
Vice President
Advanced Internal Medicine Group, P.C.
East Hills, NY

Dr. Morales receives consulting fees from and is on the speakers’ bureaus for Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, and Novo Nordisk.

Joel Zonszein, MD, CDE, FACP, FACE
Professor of Medicine
Albert Einstein College of Medicine
Department of Medicine
Division of Endocrinology and Metabolism
Montefiore Medical Center
The University Hospital for
  Albert Einstein College of Medicine
Bronx, NY

Dr. Zonszein is a consultant for Boehringer Ingelheim, Merck/Schering-Plough Pharmaceuticals, and Novo Nordisk. He is on the speakers’ bureaus for Boehringer Ingelheim and Novo Nordisk.

CONTRIBUTING FACULTY
Helena Duffy, ANP-BC, CDE

Montefiore Clinical Diabetes Center
Bronx, NY

Ms. Duffy has no relevant financial relationships to disclose.

Edwin Torres MS, RN, CHNP, FNP-C
Montefiore Clinical Diabetes Center
Bronx, NY

Mr. Torres has no relevant financial relationships to disclose.

Silvie Georgens, PA-C, RD, CDE
Diabetes and Endocrine Associates
La Jolla, CA

Dr. Georgens receives fees for promotional talks for Health-Scripts and Janssen Pharmaceuticals.

Andrea Stallings, PA-C
Diabetes and Endocrine Associates
La Jolla, CA

Dr. Stallings has no relevant financial relationships to disclose.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Credit Information

Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Sanofi US. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the CME accreditation of this activity, please contact please contact HME at cmequestions@haymarketmedical.com.

If you have any other questions relating to your certificate or other issues with the activity, please contact
myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue